English / فارسی

PHR-160 Oral inhaler

PHR Oral Inhaler 300 micrograms is recommended for treatment of 2019-nCoV lung injury. (Specially for improve oxygen saturation.)
Regular use of PHR-160 has efficacy in shortening the duration of treatment length.
PHR-160 is not approved for prophylaxis of 2019-nCoV.


Drug function

PHR-160 is as an activator of CFTR without influence on NBC1/AE although all of these transporters are commonly under the control of cAMP.
The heterologous regulation of these transporters possibly occurs due to cytoskeleton-dependent/cAMP-independent modulation of these anion transporters.
The unique effects of PHR-160 have, at least in part, the potential to ameliorate these lung diseases.

Related Links

client client client